Industry-INTERPOL anti-counterfeiting agreement highlights benefits of pooled resources
An agreement between INTERPOL and 29 pharmaceutical companies, announced yesterday, will lead to the establishment of a new €4.5 million programme to combat fake medicines. The deal also demonstrates the advantages of pooling resources to work collaboratively with authorities against shared threats.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the WTR experts.
Subscribe now